Zydus’ biopharma arm acquires global proprietary rights for Progeria treatment
AHMEDABAD: Sentynl Therapeutics Inc (Sentynl), a US-based biopharmaceutical company wholly owned by Ahmedabad-headquartered Zydus Lifesciences, recently completed the acquisition of global proprietary rights for Zokinvy. Zokinvy is the first and only US FDA-approved treatment targeting the cause and symptoms of Progeria in young people above 12 months of age. TOP PICKS FOR YOU India’s young workforce conquers global blue-collar jobs Ola […]
Zydus’ biopharma arm acquires global proprietary rights for Progeria treatment Read More »